Prediction of Human Pharmacokinetics Based on Preclinical In Vitro and In Vivo Data

  • T. Lavé
  • O. Luttringer
  • J. Zuegge
  • G. Schneider
  • P. Coassolo
  • F.-P. Theil
Part of the Ernst Schering Research Foundation Workshop book series (SCHERING FOUND, volume 37)


During the drug discovery process, candidate compounds are screened for their main drug metabolism and pharmacokinetic (DMPK) properties (absorption, distribution, metabolic stability, excretion) to assess their potential to become new drug products. Prentis observed that, of 247 new chemical entities which were withdrawn from drug development before 1985, 198 (80%) failed because of inappropriate pharmacokinetics (Prentis et al. 1988). Kennedy confirmed this conclusion in 1997 by reporting that, apart from a lack of efficacy, poor pharmacokinetic properties were still the main reason for terminating the development of drug candidates (Kennedy 1997). Nowadays, the drop out rate because of pharmacokinetic reasons has probably decreased because DMPK issues are being considered in the discovery process. Therefore, approaches to predict human pharmacokinetic profiles are highly desirable to help select the best candidates for development and/or to reject those with a low probability of success. This can drastically reduce the time and expense of drug development (Norris et al. 2000). Since drug discovery has to screen a large number of compounds, the methods used must be capable of predicting the human pharmacokinetics from a limited set of input data.


PBPK Model Allometric Scaling Liver Blood Flow Observe Plasma Concentration Human Pharmacokinetic 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Arundel PA (1997) A multi-compai rental model generally applicable, to physiologically-based pharmacokinetics. In: The third IFAC symposium. Modeling and control in biomedical systems. The institute of measurement and control, LondonGoogle Scholar
  2. Bayliss MK, Bell JA, Jenner WN, Park GR, Wilson K (1999) Utility of hepatocytes to model species differences in the metabolism of loxtidine and to predict pharmacokinetic parameters in rat, dog and man. Xenobiotica 29: 253–268PubMedCrossRefGoogle Scholar
  3. Bernareggi A, Rowland M (1991) Physiologic modeling of cyclosporin kinetics in rat and man. J Pharmacokinet Biopharm 19: 21–50PubMedGoogle Scholar
  4. Boxenbaum H (1984) Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm. Drug Metab Rev 15: 1071–1121PubMedCrossRefGoogle Scholar
  5. Boxenbaum H, Fertig JB (1984) Scaling of antipyrine intrinsic clearance of unbound drug in 15 mammalian species. Eur J Drug Metab Pharmacokinet 9: 177–183PubMedCrossRefGoogle Scholar
  6. Boxenbaum B, D’ Souza RW (1990) Interspecies pharmacokinetic scaling, biological design and neoteny. In: Testa B (ed) Advances in drug research. Academic Press, London, pp 139–196Google Scholar
  7. Boxenbaum H, Dilea C (1995) First-time-in-human dose selection: Allometric thoughts and perspectives. J Clin Pharmacol 35: 957–966Google Scholar
  8. Campbell DB (1994) Can allometric interspecies scaling be used to predict human kinetics. Drug Inf J 28: 235–245CrossRefGoogle Scholar
  9. Carlile DJ, Zomorodi K, Houston JB (1997) Scaling factors to relate drug metabolic clearance in hepatic microsomes, isolated hepatocytes, and the intact liver: Studies with induced livers involving diazepam. Drug Metab Dispos 25: 903–911Google Scholar
  10. Cross DM, Bayliss MK (2000) A commentary on the use of hepatocytes in drug metabolism studies during drug discovery and development. Drug Met Rev 32: 219–240CrossRefGoogle Scholar
  11. Houston JB (1994a) Relevance of in vitro kinetic parameters to in vivo metabolism of xenobiotics. Toxicol In Vitro 8: 507–512PubMedCrossRefGoogle Scholar
  12. Houston JB (1994b) Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47: 1469–1479PubMedCrossRefGoogle Scholar
  13. Houston JB, Carlile DJ (1997) Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. Drug Met Rev 29: 891–922CrossRefGoogle Scholar
  14. Iwatsubo T, Hirota N, Ooie T, Suzuki H, Sugiyama Y (1996) Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics. Biopharm Drug Dispos 17: 273–310PubMedCrossRefGoogle Scholar
  15. Iwatsubo T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA, Yokoi T, Kamataki T, Sugiyama Y (1997) Prediction of in vivo hepatic metabolic clearance of YM796 from in vitro data by use of human liver microsomes and recombinant P-450 isozymes. J Pharmacol Exp Ther 282: 909–919PubMedGoogle Scholar
  16. Izumi T, Enomoto S, Hosiyama K, Sasahara K, Shibukawa A, Nakagawa T, Sugiyama Y (1996) Prediction of the human pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent, after oral administration, with an animal scale-up approach. J Pharmacol Exp Ther 277: 1630–1641PubMedGoogle Scholar
  17. Kennedy T (1997) Managing the drug discovery/development interface. Drug Discovery Today 2: 436–444CrossRefGoogle Scholar
  18. Lave T, Coassolo P (1998) Commentary on “integration of in vitro data and brain weight in allometric scaling to predict clearance in humans: Some suggestions”. J Pharm Sci 87: 530Google Scholar
  19. Lave T, Coassolo P, Reigner B (1999a) Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro-in vivo correlations. Clin Pharmacokinet 36: 211–231PubMedCrossRefGoogle Scholar
  20. Lave T, Levettrafit B, Schmitthoffmann AH, Morgenroth B, Richter W, Chou RC (1995) Interspecies Scaling of Interferon Disposition and Comparison of Allometric Scaling With Concentration-Time Transformations. J Pharm Sci 84: 1285–1290PubMedCrossRefGoogle Scholar
  21. Lave T, Dupin S, Schmitt C, Chou RC, Jaeck D, Coassolo P (1997a) Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: Application to 10 extensively metabolized drugs. J Pharm Sci 86: 584–590PubMedCrossRefGoogle Scholar
  22. Lave T, Saner A, Coassolo P, Brandt R, Schmitt Hoffmann AH, Chou RC (1996a) Animal pharmacokinetics and interspecies scaling from animals to man of lamifiban, a new platelet aggregation inhibitor. J Pharm Pharmacol 48: 573–577PubMedCrossRefGoogle Scholar
  23. Lave T, Portmann R, Schenker G, Gianni A, Guenzi A, Girometta MA, Schmitt M (1999b) Interspecies pharmacokinetic comparisons and allometric scaling of napsagatran, a low molecular weight thrombin inhibitor. J Pharm Pharmacol 51: 85–91PubMedCrossRefGoogle Scholar
  24. Lave T, Coassolo P, Ubeaud G, Brandt R, Schmitt C, Dupin S, Jaeck D, Chou RC (1996b) Interspecies scaling of bosentan, a new endothelin receptor antagonist and integration of in-vitro data into allometric scaling. Pharmaceut Res 13: 97–101CrossRefGoogle Scholar
  25. Lave T, Dupin S, Schmitt C, Valles B, Ubeaud G, Chou RC, Jaeck D, Coassolo P (1997b) The use of human hepatocytes to select compounds based on their expected hepatic extraction ratios in humans Pharmaceut Res 14: 152–155Google Scholar
  26. Lave T, Schmitt-Hoffmann AH, Coassolo P, Ubeaud G, Vallès B, Ba B, Brandt R, Chou RC (1995b) A new extrapolation method from animal to man; application to a metabolized compound, mofarotene. Life Sci 56: 473–478CrossRefGoogle Scholar
  27. Lave T, Dupin S, Schmitt M, Kapps M, Meyer J, Morgenroth B, Chou RC, Jaeck D, Coassolo P (1996c) Interspecies scaling of tolcapone, a new inhibitor of catechol-0- methyltransferase ( COMT) Use of in vitro data from hepatocytes to predict metabolic clearance in animals and humans. Xenobiotica 26: 839–851Google Scholar
  28. Lin JH (1998) Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics. Drug Metab Dispos 26: 1202–1212PubMedGoogle Scholar
  29. Lin JH, Sugiyama Y, Awazu S, Hanano M (1982) Physiological pharmacokinetics of ethoxybenzamide based on biochemical data obtained in vitro as well as on physiological data. J Pharmacol Exp Ther 10: 649–661Google Scholar
  30. Mordenti J (1985) Pharmacokinetic scale-up: accurate prediction of human pharmacokinetic profiles from animal data. J Pharm Sci 74: 1097–1099PubMedCrossRefGoogle Scholar
  31. Mordenti J (1986) Man versus beast: pharmacokinetic scaling in mammals. J Pharm Sci 75: 1028–1040PubMedCrossRefGoogle Scholar
  32. Norris DA, Leesman GD, Sinko PJ, Grass GM (2000) Development of predictive pharmacokinetic simulation models for drug discovery. J Control Rel 65: 55–62CrossRefGoogle Scholar
  33. Obach RS (1996) The importance of nonspecific binding in in vitro matrices, its impact on enzyme kinetic studies of drug metabolism reactions, and implications for in vitro-in vivo correlations (letter) Drug Metab Dispos 24: 1047–1049PubMedGoogle Scholar
  34. Obach RS (1999) Prediction of human clearance of 29 drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27: 1350–1359PubMedGoogle Scholar
  35. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, Maclntyre F, Rance DJ, Wastall P (1997) The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283: 46–58PubMedGoogle Scholar
  36. Poulin P, Theil FP (2000) A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. J Pharm Sci 89: 16–35PubMedCrossRefGoogle Scholar
  37. Poulin P, Schoenlein K, Theil F (2001) Prediction of adipose tissue: Plasma partition coefficients for structurally unrelated drugs. J Pharm Sci 90: 436–447Google Scholar
  38. Prentis RA, Lis Y, Walker SR. (1988) Pharmaceutical innovation by the seven UK-owned companies (1964–1985) Br J Clin Pharmacol 25: 387–396PubMedGoogle Scholar
  39. Richter WF, Heizmann P, Meyer J, Starke V, Lave T (1998) Animal pharmacokinetics and interspecies scaling of Ro 25–6833 and related (lactamylvinyl)cephalosporins. J Pharm Sci 87: 496–500PubMedCrossRefGoogle Scholar
  40. Schneider G, Coassolo P, Lave T (1999) Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural. networks and multivariate statistical techniques. J Med Chem 42: 5072–5076PubMedCrossRefGoogle Scholar
  41. Schuhmann G, Fichtl B, Kurz H (1987) Prediction of drug distribution in vivo on the basis of in vitro binding data. Biopharm Drug Dispos 8: 73–86PubMedCrossRefGoogle Scholar
  42. Zuegge J, Schneider G, Coassolo P, Lave T (2001) Prediction of hepatic metabolic clearance in man — comparison and assessment of prediction models. Clin Pharmacokinet 40: 553–563PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2002

Authors and Affiliations

  • T. Lavé
  • O. Luttringer
  • J. Zuegge
  • G. Schneider
  • P. Coassolo
  • F.-P. Theil

There are no affiliations available

Personalised recommendations